Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prasinezumab versus placebo in early-stage Parkinson's disease
NL-OMON59168Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of prasinezumab in Parkinson's disease (PD), sponsored by Roche. Primary endpoint: Time to confirmed motor progression event. Started Dec 2025; status: completed.
02
Drugs
prasinezumab
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON59168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59168.